EP1157110A4 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant

Info

Publication number
EP1157110A4
EP1157110A4 EP00908739A EP00908739A EP1157110A4 EP 1157110 A4 EP1157110 A4 EP 1157110A4 EP 00908739 A EP00908739 A EP 00908739A EP 00908739 A EP00908739 A EP 00908739A EP 1157110 A4 EP1157110 A4 EP 1157110A4
Authority
EP
European Patent Office
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00908739A
Other languages
German (de)
French (fr)
Other versions
EP1157110A1 (en
Inventor
Craig A Rosen
Jian Ni
Reinhard Ebner
Guo-Liang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/255,794 external-priority patent/US6716576B1/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP07012741A priority Critical patent/EP1860190A3/en
Publication of EP1157110A1 publication Critical patent/EP1157110A1/en
Publication of EP1157110A4 publication Critical patent/EP1157110A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP00908739A 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variant Withdrawn EP1157110A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07012741A EP1860190A3 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variants

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US255794 1988-10-11
US09/255,794 US6716576B1 (en) 1996-10-25 1999-02-23 Method of assaying Neutrokine-α mRNA level
US12238899P 1999-03-02 1999-03-02
US122388P 1999-03-02
US12409799P 1999-03-12 1999-03-12
US124097P 1999-03-12
US12659999P 1999-03-26 1999-03-26
US126599P 1999-03-26
US12759899P 1999-04-02 1999-04-02
US127598P 1999-04-02
US13041299P 1999-04-16 1999-04-16
US130412P 1999-04-16
US13069699P 1999-04-23 1999-04-23
US130696P 1999-04-23
US13127899P 1999-04-27 1999-04-27
US131278P 1999-04-27
US13167399P 1999-04-29 1999-04-29
US131673P 1999-04-29
US13678499P 1999-05-28 1999-05-28
US136784P 1999-05-28
US14265999P 1999-07-06 1999-07-06
US142659P 1999-07-06
US14582499P 1999-07-27 1999-07-27
US145824P 1999-07-27
US16723999P 1999-11-24 1999-11-24
US167239P 1999-11-24
US16862499P 1999-12-03 1999-12-03
US168624P 1999-12-03
US17110899P 1999-12-16 1999-12-16
US171108P 1999-12-16
US17162699P 1999-12-23 1999-12-23
US17601500P 2000-01-14 2000-01-14
US176015P 2000-01-14
PCT/US2000/004336 WO2000050597A2 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variant
US171626P 2009-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07012741A Division EP1860190A3 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variants

Publications (2)

Publication Number Publication Date
EP1157110A1 EP1157110A1 (en) 2001-11-28
EP1157110A4 true EP1157110A4 (en) 2006-05-10

Family

ID=27586018

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00908739A Withdrawn EP1157110A4 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variant
EP07012741A Withdrawn EP1860190A3 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variants

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07012741A Withdrawn EP1860190A3 (en) 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variants

Country Status (6)

Country Link
EP (2) EP1157110A4 (en)
JP (2) JP2003526330A (en)
AU (2) AU777536B2 (en)
CA (1) CA2363112A1 (en)
NZ (2) NZ513290A (en)
WO (1) WO2000050597A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DK1146892T3 (en) 1999-01-25 2003-11-24 Apoxis Sa BAFF, its inhibitors and their use in modulating the B cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
WO2000068378A1 (en) 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
US6969519B2 (en) 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences Antibodies against tumor necrosis factor delta (april)
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
JP2008528633A (en) * 2005-02-01 2008-07-31 リサーチ ディベロップメント ファウンデーション BLYS fusion proteins for targeting BLYS receptors and methods of treating B cell proliferative disorders
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (en) 2005-08-09 2012-02-28 Займоджинетикс, Инк. Methods for treating b-non-hodgkin's lymphoma using taci-ig fusion molecule
NZ568204A (en) 2005-10-13 2012-01-12 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (en) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Compositions and methods for B cell assays.
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101489573B (en) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
JP2010509235A (en) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ Treatment of multiple sclerosis
CA2694454A1 (en) * 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO2000050597A2 (en) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6403770B1 (en) * 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EA200000311A1 (en) * 1997-09-12 2000-10-30 Апотек Р Энд Д Са NEW PROTEIN IMMUNE SYSTEM - KAU
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
US6403770B1 (en) * 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha
WO2000050597A2 (en) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200053, Derwent World Patents Index; Class B04, AN 2000-572093, XP002331367 *

Also Published As

Publication number Publication date
JP2007277249A (en) 2007-10-25
AU2005200237A1 (en) 2005-02-17
CA2363112A1 (en) 2000-08-31
WO2000050597A2 (en) 2000-08-31
AU2005200237B2 (en) 2007-11-29
EP1157110A1 (en) 2001-11-28
AU3002800A (en) 2000-09-14
AU777536B2 (en) 2004-10-21
NZ529555A (en) 2005-09-30
EP1860190A3 (en) 2008-03-12
NZ513290A (en) 2004-05-28
JP2003526330A (en) 2003-09-09
EP1860190A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
EP1157110A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
HRP20060251B1 (en) Substituted oxasolidinones and their use
EP1309718A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
AU3620600A (en) Skin-marking devices and their use
GB9712347D0 (en) Vaccine
GB9711990D0 (en) Vaccine
EP1507793A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
GB2350631B (en) Combination whipstock and anchor
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB2352523B (en) Fluid-gauging systems and methods
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
EP1194147A4 (en) Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9704349D0 (en) Levobupivacaine and its use
TW424891U (en) Holding and fixing structure
NO991348L (en) Oljebr ° When ° r
EP1229913A4 (en) Substituted 1-benzazepines and derivatives thereof
IL129907A0 (en) Alternative splice variants
GB0021915D0 (en) Creating and managing E-receipts
AU2669201A (en) Taccalonolides and their use
GB9704370D0 (en) Levobupivacaine and its use
HK1046707A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant
GB9929581D0 (en) Comjpositions and their use
GB2354395B (en) Telephone system and circuitry
GB2389158B (en) Anchorage
GB9722023D0 (en) Levobupivacaine and its use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010924

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060328

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070630

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046707

Country of ref document: HK